#United States #Breast Cancer #Germantown #IceCure #ChoICE Study

West Cancer Center Initiates IceCure's Innovative ChoICE Study for Breast Cancer Treatment

In a significant advancement for breast cancer treatment, the West Cancer Center has announced its receipt of Institutional Review Board (IRB) approval to launch the ChoICE Study, spearheaded by IceCure Medical Ltd. This study focuses on the use of ProSense® cryoablation technology, which is a minimally invasive method aimed at treating low-risk breast cancer in patients aged 70 years and older.

A Leap Forward in Cryoablation Technology

IceCure Medical, listed on NASDAQ under the ticker ICCM, specializes in innovative cryoablation techniques that effectively freeze and destroy tumors, providing an alternative to traditional surgical tumor removal. The ChoICE Study, approved by the JHM-IRB at West Cancer Center Research Institute located in Germantown, TN, is geared towards expanding options for patients favoring less invasive interventions.

With enrollment expected to start in the forthcoming weeks, this study builds on prior successful outcomes demonstrated in the ICE3 clinical trial, where ProSense® cryoablation combined with endocrine therapy resulted in only a 3.1% local recurrence rate among participants suffering from early-stage, low-risk breast cancer. The trial achieved remarkable satisfaction rates, with 99.1% of patients and 97% of physicians expressing their approval regarding the cosmetic results of the treatment.

Study Overview

The ChoICE Study will enroll 400 patients, utilizing 30 different participating sites serving as both clinical trial centers and commercial referral facilities. This dual approach not only promises access to the latest technology for participants but also for eligible patients outside the study, reflecting an increased demand for alternatives to conventional surgical methods.

ProSense® is particularly significant as it has become the first FDA-authorized device specifically approved for treating local low-risk breast cancer via endocrine therapy among women aged 70 and older. This landmark approval confirms the product's readiness for real-world application, offering hope and convenience to older women facing breast cancer diagnoses, especially those not candidates for surgery.

The Clinical Leadership and Commitment to Care

Under the guidance of Dr. Richard Gilmore, a well-respected breast surgical oncologist at the Margaret West Comprehensive Breast Center, the ChoICE Study aims to further validate cryoablation’s effectiveness in low-risk cases. This study underscores IceCure's commitment to transforming cancer care and its dedication to supporting patients by providing a less invasive treatment option.

In addition to this, the West Cancer Center Research Institute has maintained a stellar reputation for over 47 years, being recognized as a leader in adult cancer care. Their combination of advanced technology and a patient-centered approach ensures high standards of treatment and care, striving for the best possible outcomes.

Final Thoughts

As the medical community progresses toward adopting less invasive treatment modalities, IceCure’s ChoICE Study emerges as a beacon of hope for patients battling breast cancer. With its roots in innovative technology and commitment to patient satisfaction, the study is set to reshape how low-risk breast cancer is treated, paving the way toward a brighter future in cancer treatment.

For additional information regarding eligibility for the ChoICE trial or to schedule appointments, interested patients are encouraged to reach out to the Margaret West Comprehensive Breast Center.

IceCure Medical continues to be at the forefront of medical innovation, focusing on enhancing treatment options in areas such as breast, kidney, bone, and lung cancers. With an unwavering goal to enhance patient lives, IceCure remains dedicated to pushing boundaries in the treatment landscape.